Type II diabetes: Synjardy® approved in the EU
Synjardy® has been granted marketing authorisation by the European Commission for the treatment of adults with type II diabetes (T2D) in the European Union (EU). Synjardy® is a new single-pill combination therapy from the Boehringer Ingelheim and Eli Lilly and Company diabetes alliance.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Diabetes blood glucose-lowering drugs empagliflozin glycaemic control Jardiance Latest News metformin odium glucose cotransporter 2 SGLT2 synjardy T2D Source Type: news
More News: Clinical Trials | Diabetes | Drugs & Pharmacology | Empagliflozin | Endocrinology | Fortamet | Jardiance | Marketing | Metformin | SGLT2 Inhibitors